1030-33-7

Usage

Uses

Used in Pharmaceutical Development:
PI-7-C is utilized as a ligand for GABA receptors, leveraging its interaction with these receptors to potentially treat neurological disorders associated with GABAergic dysfunction.
Used in Anticonvulsant Medications:
As an anticonvulsant, PI-7-C is employed for its capacity to prevent or reduce the frequency of seizures, offering a potential therapeutic option for epilepsy and other seizure disorders.
Used in Neurotransmitter Release Modulation:
PI-7-C serves as a modulator of neurotransmitter release, which can be significant in the treatment of various neurological and psychiatric conditions by influencing synaptic transmission.
Used in Anti-inflammatory Applications:
PI-7-C is applied for its potential anti-inflammatory properties, which may be beneficial in the management of conditions characterized by inflammation, such as arthritis or autoimmune diseases.
Used in Analgesic Formulations:
Harnessing its analgesic potential, PI-7-C is used in the development of pain relief medications, offering a possible alternative or adjunct to existing analgesics.
Used in Drug Delivery Systems:
In the context of drug delivery, PI-7-C may be integrated into systems designed to improve the bioavailability and targeting of therapeutic agents, potentially enhancing the efficacy and safety of treatments.

InChI:InChI=1/C15H12N2O2/c1-19-15(18)12-7-8-17-10-13(16-14(17)9-12)11-5-3-2-4-6-11/h2-10H,1H3

Upstream product

• 6937-03-7 methyl 2-aminoisonicotinate 
• 98-86-2 acetophenone 
• 7257-94-5 1-phenyl-2-(p-tolylsulfonyloxy)ethanone 
• 70-11-1 α-bromoacetophenone 

Downstream Products

• 1278406-63-5 4-Chloro-2-methyl-2H-pyrazole-3-carboxylic acid (2-phenyl-imidazo[1,2-a]pyridin-7-yl)-amide 
• 959-40-0 2-phenylimidazo[1,2-a]pyridine-7-carboxylic acid 
• 1278407-53-6 tert-butyl 2-phenylimidazo[1,2-a]pyridin-7-ylcarbamate 
• 1278407-54-7 2-phenylimidazo[1,2-a]pyridin-7-ylamine 

Relevant academic research and scientific papers

Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents

Free fatty acid receptor 1 (FFA1 or GPR40) has been studied for many years as a target for the treatment of type 2 diabetes mellitus. In order to increase potency and reduce hepatotoxicity, a series of novel compounds containing imidazo[1,2-a]pyridine sca

General Method for the Preparation of Electron-Deficient Imidazo[1,2-a]pyridines and Related Heterocycles

A new annulation method for the preparation of the imidazo[1,2-a]pyridine ring system under mild conditions is presented. Treatment of a 2-aminopyridine with a dimethylketal tosylate in acetonitrile at elevated temperature (80-140°C) in the presence of catalytic Sc(OTf)3 provides the imidazo[1,2-a]pyridine product in good yield. The annulation method is broadly applicable to electron-poor 2-aminopyridines and displays a complementary profile to the classic preparation of the imidazo[1,2-a]pyridine ring system by reaction of a bromoketone with electron-rich and -neutral substrates. The scope of the process and mechanistic considerations are discussed.

NOVEL IMIDAZOPYRIDINES

The invention is concerned with novel imidazopyridine derivatives of formula (I) wherein R1, R2, R3, R4, R5 and A are as defined in the description and in the claims, as well as physiologically accept

IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS

The invention is concerned with novel imidazopyridine derivatives of formula (I) wherein R1, R2, R3, R4, R5 and A are as defined in the description and in the claims, as well as physiologically accept